Main results
One study was included in the review. This multi-centre trial was based in five Australian hospitals and recruited 272 children with chronic cough. Children were randomly assigned to early (two weeks) or delayed (six weeks) referral to respiratory specialists who used a cough management pathway. When an intention-to-treat analysis was performed, clinical failure at six weeks post randomisation (defined as < 75% improvement in cough score, or total resolution for fewer than three consecutive days) was significantly less in the early pathway arm compared with the control arm (odds ratio (OR) 0.35, 95% confidence interval (CI) 0.21 to 0.58). These results indicate that one additional child will be cured for every five children treated via the cough pathway (number needed to treat for an additional beneficial outcome (NNTB) = 5, 95% CI 3 to 9) at six weeks. Cough-specific parent-reported quality of life scores were significantly better in the early-pathway group; the mean difference (MD) between groups was 0.60 (95% CI 0.19 to 1.01). Duration of cough post randomisation was significantly shorter in the intervention group (early-pathway arm) compared with the control group (delayed-pathway arm) (MD -2.70 weeks, 95% CI -4.26 to -1.14).
Authors' conclusions
Current evidence suggests that using a clinical algorithm for the management of children with chronic cough in hospital outpatient settings is more effective than providing wait-list care. Futher high-quality randomised controlled trials are needed to perform ongoing evaluation of cough management pathways in general practitioner and other primary care settings.
P L A I N L A N G U A G E S U M M A R Y

Clinical pathways for chronic cough in children Background
Clinical pathways serve as a tool or algorithm (like a flow chart) that can be used in the treatment of patients with various chronic diseases. They provide a clear guide that assists doctors in diagnosing an illness and in making decisions with the patient about what treatment is needed or which specialists should be seen or tests ordered at each stage of progression of the disease. Overall the aim of clinical pathways is to provide efficient care for patients. Examples of patient decision aids are provided by the National Health Service (NHS) in the UK at http://www.rightcare.nhs.uk/index.php/shared-decision-making/about-the-pdas/.
Chronic cough in children is a significant medical problem that in some situations warrants thorough investigation. This review examined whether using clinical pathways was effective for evaluating and managing children with chronic cough (cough lasting longer than 4 weeks).
Study characteristics
Only a single multi-centre study could be included in this review. Evidence is current to January 2014. This study was funded by the National Health and Medical Research Council of Australia.
Key results
This study of 272 children in five Australian hospitals reported that those randomly assigned to earlier treatment according to a clinical pathway showed improved clinical outcomes (cough resolved earlier and quality of life was better) compared with those who were randomly assigned to later use of the pathway. No adverse events were reported.
Quality of the evidence
The quality of evidence was graded as moderate. Evidence is limited, as only one study could be included in this review. This study was unable to completely blind participants to the clinical pathway.
Outcomes
Illustrative comparative risks* (95% CI) Relative effect (95% CI) a A single study was identif ied, and com plete blinding was not possible f or this type of intervention.
No. of participants (studies)
Quality of the evidence (GRADE)
Comments
B A C K G R O U N D
Description of the condition
Cough is the most common symptom presenting to primary care internationally (Britt 1999; Cherry 2003; Irwin 2006) . In Australia, 5.8 of every 100 visits to general practitioners are result of cough (Britt 2008). Chronic (prolonged) cough is also one of the most common symptoms presenting to respiratory physicians (Fitzgerald 2006) . Thus, in Australia alone, these visits on a population level would equate to millions of dollars per year in Medicare rebates for general practitioner (GP) visits. Further, studies have shown that more than 80% of children who have seen specialists for chronic cough have had more than five medical visits, and over 20% had seen a doctor more than 20 times (Chang 2012; Marchant 2008 
Description of the intervention
The major aim of clinical pathways or guidelines is to improve diagnosis and/or management of the specific condition or symptom. They provide a step-by-step approach for the clinician that is based on preceding criteria. 
O B J E C T I V E S
To evaluate the effectiveness of using a clinical pathway in the management of children with chronic cough.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs of parallel-group design comparing use versus non-use of a clinical pathway for the treatment of children with chronic cough.
Types of participants
Inclusion criteria: children (< 18 years of age) with chronic (lasting longer than four weeks) cough of unknown origin. Exclusion criteria: known preexisting respiratory illness causing cough.
Types of interventions
All randomised controlled comparisons of use of a clinical pathway. Review authors planned that trials examining use of other medications or interventions would be included if all participants were given equal access to such medications or interventions.
Types of outcome measures
Primary outcomes
Proportions of participants who were not cured or were not substantially improved at follow-up (clinical failure).
Secondary outcomes
1. Proportions of participants who were not cured at followup.
2. Proportions of participants who were not substantially improved at follow-up.
3. Mean difference in cough indices (cough diary, cough frequency, cough-specific quality of life scores, cough duration).
4. Proportions of participants experiencing adverse effects of the intervention (e.g. Cushing's syndrome from steroid overdose).
5. Proportions of participants experiencing complications (e.g. acute hospitalisations, chronic lung disease resulting from delayed diagnosis). Proportions of participants who failed to improve while receiving treatment and mean clinical improvement were determined using the following hierarchy of assessment measures (Note: When two or more assessment measures were reported in the same study, the outcome measure listed first in the hierarchy was used).
1. Objective measurements of cough indices (cough frequency, cough receptor sensitivity). 
Search methods for identification of studies
Electronic searches
Trials were identified from the following sources.
1. The Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 1).
2. The Cochrane Airways Group Specialised Register. 3. MEDLINE (Ovid) (1950 to January 2014). 4. EMBASE (Ovid) (1980 to January 2014). Full search strategies are listed in Appendix 1. Conference abstracts were handsearched and grey literature was searched through the CENTRAL database.
Searching other resources
In addition to the electronic search, we checked the reference lists of relevant publications and contacted the authors of the included trial to ask for further information.
Data collection and analysis
Selection of studies
Retrieval of studies: Using article titles, abstracts or descriptors, two review authors (EJB and ABC in original review and search from 2009 to 2012; GBM and ABC in search from 2012 to 2014) independently reviewed literature searches to identify potentially relevant trials for full review. They conducted searches of bibliographies and texts to identify additional studies. From the fulltext articles obtained, the same two review authors independently assessed trials for inclusion on the basis of specific criteria. It was planned that disagreements would be resolved by third party adjudication (PM), but no disagreement was reported.
Data extraction and management
We had no disagreements but had planned to resolve disagreements through discussion with another review author (PSM). We extracted data using a standardised data collection form and managed them in Review Manager 5.2, in accordance with recommendations provided in the Cochrane Handbook for Systematic Review of Interventions (Higgins 2011). When required, we requested further information from trial authors.
Assessment of risk of bias in included studies
Two review authors (GBM and ABC) independently assessed risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). It was planned that disagreements would be resolved by discussion or by third party adjudication. We assessed risk of bias according to the following domains.
1. Allocation sequence generation (selection bias).
Concealment of allocation (selection bias).
3. Blinding of participants (performance bias). 4. Outcome assessment (detection bias). 5. Incomplete outcome data (attrition bias). 6. Selective outcome reporting (reporting bias).
Measures of treatment effect
For the dichotomous outcome variables of each individual study, odds ratios were calculated using a modified intention-to-treat analysis. This analysis assumes that children not available for outcome assessment have not improved (and probably represents a conservative estimate of effect). Other indices were assumed to be normally distributed continuous variables, so the mean difference in outcomes could be estimated (weighted mean difference). It was planned that if studies reported outcomes using different measurement scales, the standardised mean difference would be used.
Unit of analysis issues
Cross-over trials are not appropriate for this intervention and therefore were not planned for inclusion in any meta-analysis performed. It was planned that cross-over trials that met other review inclusion criteria would be described in the text.
Dealing with missing data
It was planned that Investigators or study sponsors would be contacted to verify key study characteristics and to provide missing numerical outcome data when necessary.
Assessment of heterogeneity
It was planned that heterogeneity between study results would be described and tested using the I 2 statistic to ascertain whether it reached statistical significance (Higgins 2003). Heterogeneity is considered significant when the P value is less than 0.10 (Higgins 2011). As only one study was suitable for inclusion in the review, assessment of heterogeneity was not necessary.
Assessment of reporting biases
If reporting bias was suspected (see 'Selective reporting bias' in the 'Risk of bias' table below), we planned to contact study authors to ask them to provide missing outcome data. It was planned that if missing data were not provided, and if this was thought to introduce serious bias, the impact of including such studies in the overall assessment would be explored through a sensitivity analysis.
As a single study with complete outcome reporting was included in this review update, sensitivity analysis was not required.
Data synthesis
An initial qualitative comparison of all individually analysed studies was planned to examine whether pooling of results (meta-analysis) was reasonable. This comparison would have taken into account differences in study populations, inclusion/exclusion criteria, interventions, outcome assessment and estimated effect size. Results from studies that met the inclusion criteria and reported any of the outcomes of interest would have been included in subsequent meta-analyses. However, as only one study was suitable for inclusion (based on study characteristics and inclusion criteria of this review), a qualitative comparison of studies was not required. We created a 'Summary of findings' table (SoF) (Summary of findings for the main comparison) in accordance with methods and recommendations described in Section 8. 5 and Chapter 12 of the Cochrane Handbook for Systematic Review of Interventions (Higgins 2011) and using GRADEpro software. The summary weighted odds ratio (OR) and 95% confidence interval (95% CI) (fixed-effect model) were calculated using RevMan. Numbers needed to treat for an additional beneficial outcome (NNTB) were calculated from the pooled OR, and its 95% CI was applied to a specified baseline risk with use of an online calculator (Cates 2003) .
Subgroup analysis and investigation of heterogeneity
We had planned a priori subgroup analyses for children younger than seven years of age and for those seven years of age and older.
As only a single study was identified for inclusion in the review, subgroup analyses and investigations of heterogeneity were not performed.
Sensitivity analysis
Sensitivity analyses were planned to assess the impact of potentially important factors on overall outcomes. 1. Analysis by type of clinical pathway (e.g. continentspecific).
2. Analysis by setting, whereby frequency of causes of chronic cough may be different (e.g. general practitioners vs specialists, affluent vs non-affluent countries, indigenous vs mainstream communities).
3. Analysis using a random-effects model. 4. Analysis by "treatment received." 5. Analysis by "intention-to-treat." As only a single study was included, subgroup (described above) and sensitivity analyses were not performed.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of excluded studies.
Results of the search
Combined searches (original and update reviews) performed by the Cochrane Airways Group identified 727 potentially relevant titles. After the abstracts were assessed, 10 studies were considered for inclusion in the review, and one study (Chang 2013 ) fulfilled the eligibility criteria of the review (Figure 1) .
Included studies
The sole study included in the review was a multi-centre study supported by a competitive, non-commercial grant (National Health and Medical Research Council of Australia). The study protocol was published previously (Chang 2010) . Study authors described the trial as a pragmatic RCT (Chang 2013) utilising a standardised clinical management pathway for management of chronic cough in children (i.e. two weeks (early) vs six weeks (delayed) of referral by their referring physician). Children were randomly assigned by their referring physician to an early management pathway (within three weeks of referral to the specialist practice) or to usual care (i.e. later management with the pathway around the six-week waiting period required to obtain a regularly scheduled specialist appointment) (Chang 2013 ). The RCT did not strictly explore intervention versus standard care (i.e. use vs non-use of a clinical pathway), as all participants received the intervention within the timing of the intervention (i.e. merely delayed). Study authors justified the study design by stating that a cluster-blind RCT would not be feasible, as all centres involved in the study had similar standard clinical practices, in line with current recommendations (upon which the cough pathway was designed), and physicians were not comfortable withholding treatment for the purpose of a study. Similarly, the study authors acknowledged that strict time point adherence (rather than "early" and "delayed" use of the pathway) would introduce greater rigour to the study but stated that a pragmatic design was required for the real-life clinical settings in which the study operated (Chang 2013 ). This study was conducted in paediatric hospital outpatient clinics at five centres in Australia, and investigators recruited children who were newly referred with chronic cough (lasting longer than four weeks). A total of 272 participants were included in the study; 152 were male. The mean age of study participants was 4.5 (standard deviation (SD) 3.7) years, and the median duration of cough at enrolment was 16 (interquartile range (IQR) 8 to 32) weeks (Chang 2013) . Nineteen children were not treated according to the clinical pathway, as they did not attend their first scheduled appointment with the respiratory physician (n = 8 from the intervention group; n = 11 from the control group). A further 22 children were withdrawn from the study (parents withdrew n = 3; lost to follow-up n = 17; protocol violation n = 1; non-adherence n = 1). Baseline data for 253 participants were therefore available, as were complete primary outcome data for 226 participants. Although the study was undertaken to evaluate outcome measures four weeks post use of the pathway in the early-pathway arm and before use of the pathway in the delayed-pathway arm, participating children were seen (hence the pathway was used) at 1.9 (SD 1) weeks and 5.1 (SD 1.8) weeks, respectively. Outcomes of the study were likely diluted.
The study used proportions of cough-free (> 75% improvement in cough or total resolution of cough for three or more days according to cough diary) children and parent-proxy quality of life score, both measured at week six, as the primary outcome measures. Excluded were children with a known chronic respiratory illness (previously diagnosed by a respiratory physician or confirmed on objective tests) such as cystic fibrosis or bronchiectasis. For further details, see Characteristics of included studies.
Excluded studies
Nine studies were excluded (see Characteristics of excluded studies) because they used a non-RCT design or did not use a specific management protocol for cough treatment.
Risk of bias in included studies
Risk of bias in the included study is summarised in Figure 2 and Figure 3 .
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as
percentages across all included studies.
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Allocation
Assessed as low risk of bias. Study authors clearly described computer-generated randomisation sequencing with concealed allocation.
Blinding
Assessed as low risk of bias. Although participants and research personnel collecting data were not specifically informed about the study arm to which they were allocated, the design of the study made complete blinding not feasible. At the time the study was conducted, the usual wait time to see a clinician in the public health setting was used as the time frame for the delayed-pathway arm (control) (i.e. around six weeks) and usual wait time for pri-vate clinics was used as the time frame for the early-pathway arm (intervention) (one to three weeks). Regarding the objective character of outcome measures, we did not expect high risk of bias with clinical failure. With regards to subjective outcome measures, we do not expect high risk of bias for parent-reported cough-specific quality of life score (PC-QOL), as a standardised approach was implemented for all study participants.
Incomplete outcome data
Assessed as low risk of bias. Study authors (Chang 2013) stated that complete outcome data were obtained in more than 90% of participants.
Selective reporting
Assessed as low risk of bias, with study authors clearly describing in the published manuscript the progress of all randomly assigned participants. Limitations of the study were identified and discussed by the study authors.
Other potential sources of bias
The number of potentially eligible participants who were not enrolled (declined participation or were not approached for participation) is not stated by the study authors. This may introduce an unclear assessment of recruitment selection bias.
Effects of interventions
See: Summary of findings for the main comparison
As only one study met the criteria for inclusion in this review, no meta-analysis could be performed. The effects of intervention presented below are reported by the single included study (Chang 2013 ).
Primary outcome
Proportions of participants who were not cured or were not substantially improved at follow-up (clinical failure)
Intention-to-treat analysis revealed that clinical failure was significantly lower in the early-pathway arm (intervention) compared with the delayed-pathway arm (control) (OR 0.35, 95% CI 0.21 to 0.58; Analysis 1.1), as presented in Figure 4 . The control event rate (i.e. the number of clinical failures reported from the control group) was 70.5% versus the intervention event rate of 46% (Chang 2013 ). These results indicate that one child will be cured for every five children treated by using the cough pathway at six weeks (NNTB = 5, 95% CI 3 to 9; Cates plot, Figure 5 ). 
Secondary outcomes
Proportions of participants who were not cured at follow-up
The proportion of participants not cured at follow-up (secondary outcome) is the same as the proportion of participants with clinical failure (see primary outcome above) (Analysis 1.2).
Proportions of participants who were not substantially improved at follow-up
The study reported only on participants cured or not cured at follow-up. Participants not substantially improved were considered not cured.
Mean differences in cough indices (cough diary, cough frequency, cough-specific quality of life scores, cough duration)
The parent-reported cough-specific quality of life score (PC-QOL) at week six was significantly better (i.e. higher) for those in the early-pathway arm compared with those in the delayed-pathway arm (MD 0.60 points, 95% CI 0.19 to 1.01; Analysis 1.3). Duration of cough post randomisation was significantly shorter in the intervention group (early-pathway arm) compared with the control group (delayed-pathway arm) (MD -2.70 weeks, 95% CI -4.26 to -1.14; Analysis 1.4).
Proportions of participants experiencing adverse effects of the intervention or complications
Study authors reported that none of the participants in the intervention (pathway) group and none in the control (standard care) group experienced adverse events.
Other outcomes
Once the cough algorithm was used, irrespective of whether it was applied early or was delayed, the duration of cough was similar. Also, in contrast to results reported for a cough-specific quality of life, no differences were noted between groups in terms of generic health-related quality of life (PedsQL) score at six weeks (early arm: median 92.5, IQR 81 to 96.5; delayed arm: median 87, IQR 76 to 96.3).
D I S C U S S I O N
Summary of main results
Only a single study fulfilled the inclusion criteria. This multi-centre study involved 272 children enrolled from hospital outpatient departments in Australia. This body of evidence was graded as moderate quality through the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach. An ITT analysis revealed that clinical failure was significantly lower in the early-pathway arm (clinical review within two weeks) compared with the control arm (delayed use of pathway; clinical review at six weeks) (OR 0.35, 95% CI 0.21 to 0.58). For the secondary outcome of mean score for cough-specific parent-reported quality of life, the score was significantly better in the early-pathway group (0.60 units, 95% CI 0.19 to 1.01) compared with the control group. This is seen just at the minimum important difference (MID) (using the distribution method for calculating MID) (Newcombe 2010; Newcombe 2010b). The intervention group also had significantly shorter duration of cough post randomisation compared with the control group (MD -2.70, 95% CI -4.26 to -1.14). No adverse events were reported.
Overall completeness and applicability of evidence
Clinical pathways are used for various chronic diseases to facilitate diagnosis; aid decision making; and provide efficient care to patients. Chronic cough in children is a significant medical problem that in some situations warrants thorough investigation. This review is limited, as only data from a single study are available. Nevertheless, data support the use of clinical management pathways for chronic cough in children in a tertiary care setting. Although the RCT in this review planned to compare outcomes four weeks post use of the pathway in the early-pathway arm and before use of the pathway in the delayed-pathway arm (i.e. within six weeks of referral), pragmatically this was not feasible, and children entered the protocol at times that were not strictly adhered to, resulting in treatment of children by respiratory paediatricians in accordance with the pathway at 1.9 (SD 1) weeks and 5.1 (SD 1.8) weeks, respectively. This flexibility in treatment time means that study results are likely to be diluted, as children in the delayed-pathway arm received treatment before measurements were undertaken.
Limitations
The algorithm applied in the included study was used by respiratory physicians (all but one person was a respiratory physician); therefore, any effect that might be attributed to expertise required to use the algorithm cannot be identified. However, steps within the algorithm are simple and explicit, and most (85%) of the children had diagnoses that could be made easily in primary care. For example, key steps such as distinguishing between wet and dry cough (Chang 2005b ) and categorising specific versus non-specific cough (Marchant 2006b) are both feasible and reliable. Thus, although the same pathway could be used in general practice, treatment outcomes may be different, as the pathway is dependent on thorough history taking and examination (including identifying the presence of crepitations). In general practice, agreement of items in preschool children (most children with chronic cough are of preschool age) such as wheeze and chest examination findings has been shown to be poor (kappa values range from 0.12 to 0.39) (Hay 2004). Thus, applicability of the pathway (without concurrent education) in general practice cannot be ascertained. Further education for primary care providers on how to use the algorithm is likely required for the algorithm to be as successful as was reported in the included study. A wait-list RCT pragmatic approach was used in the included study. The design of this study is similar to the wait-list approach used for some RCTs, such as those examining psychological interventions or paediatric surgery (e.g. tonsil-adenoidectomy for obstructive sleep apnoea), for which primary outcomes are selected before the intervention is decided. Arguably, early versus delayed use of the algorithm represents an alternative valid approach (c.f. use vs non-use of an algorithm) that can be used to determine whether the algorithm is efficacious, as effectively timing the primary outcome (at week six) tests use versus non-use of the algorithm.
Quality of the evidence
Given that only one study could be included in this review, the extent of the evidence is limited. Other than the unclear risk of bias associated with blinding of participants, the risk of bias for other criteria was low. This multi-centre study involved a relatively large number of participants (i.e. for cough-related studies). The consistency of favourable outcomes in the intervention arm (including duration of cough post randomisation) supports the unlikely presence of bias. Also, the generic quality of life measure used (PedsQL), which is a less sensitive measure for cough, was not significantly different between groups, but the cough-specific quality of life score (PC-QOL) was significantly better in the early-pathway arm. Arguably, if quality of life was subject to clinically important bias, PedsQL score would also be significantly better in the intervention group (early-pathway arm) compared with the control group (delayed-pathway arm). In addition to significant differences between groups in primary outcomes (PC-QOL and proportion 'cough-free'), the duration of cough post randomisation was significantly different between groups (early-pathway vs delayed-pathway groups). Cough duration at baseline ( Table 1 in the included study) and post use of the algorithm was similar in the two groups. Thus, it is most likely that use of the algorithm accounted for differences between groups.
Potential biases in the review process
Two of the authors of this review are co-authors of the sole RCT that was included in this review. However, we took steps to reduce bias by double-entering data, and the primary author of this review was not involved in the included RCT.
Agreements and disagreements with other studies or reviews
Data from cohort studies (Asilsoy 2008; Karabel 2013; Rehman 2009) are concordant with results of this review, which included only RCTs. These cohort studies used a cough algorithm that is similar to the one described in the included study. We are not aware of any other systematic reviews with which these results can be compared.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
The limited available evidence presented here suggests that use of management protocols in the diagnosis and treatment of children with chronic cough (lasting longer than four weeks) is effective in improving clinical outcomes (cough-free, shorter duration of cough and improved parent-proxy cough-specific quality of life).
Implications for research
Further high-quality randomised controlled trials are needed for ongoing evaluation of the use of clinical pathways for the management of chronic cough in children. In these trials, settings should include general practitioner and other primary care settings and use of the cough algorithm should be compared with non-use of the algorithm. A cluster-randomised trial design is likely the most feasible study design in general practice. Use of validated cough outcome measures is essential. The ascribed diagnostic criteria and the definition of cough resolution should be decided a priori. Ideally, an objective cough outcome (such as cough counts) should also be included as an outcome.
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chang 2013
Methods
Randomised controlled trial Participants Inclusion criteria: children (< 18 years of age) with chronic cough (> 4 weeks) newly referred to specialist paediatric respiratory clinics at 5 Australian sites (Brisbane, Darwin, Melbourne, Sydney, Canberra) Exclusion criteria: children with known respiratory illness previously diagnosed by a respiratory physician or confirmed on objective testing (e.g. cystic fibrosis, bronchiectasis) before the time of referral Children assessed: n = 346 (n = 30 did not meet inclusion criteria, n = 44 declined participation) Children randomised: n = 272 (early use n = 140, delayed use n = 132) Interventions 1. Early or delayed use of an algorithm for management of cough in children (2 vs 6 weeks of referral) 2. Children randomly assigned to the early intervention arm were seen by a respiratory specialist and were managed according to the algorithm within 3 weeks of referral and study enrolment 3. Children randomly assigned to the delayed intervention arm were seen by a respiratory specialist and were managed according to the algorithm between 6 and 8 weeks of referral and study enrolment
Outcomes
Primary outcomes: 1. Proportion of children who were cough-free (considered to be 75% improvement in cough score, or total resolution for 3 consecutive days) 2. Quality of life measure (PC-QOL: cough-specific, parent-reported quality of life) at week 6
Notes
Because of the nature of the study, data collected up until the week 6 time point have been selected for inclusion in this review, as this represents use (early arm) vs non-use (delayed arm) of the algorithm. Information beyond week 6 of the study has not been included in this review MeSH descriptor Adolescent explode all trees #15 child* or paediat* or pediat* or adolesc* or infan* or toddler* or bab* or young* or preschool* or "pre school*" or pre-school* or newborn* or "new born*" or new-born* or neo-nat* or neonat* #16 (#11 OR #12 OR #13 OR #14 OR #15) #17 (#4 AND #10 AND #16)
Risk of bias Risk of bias
D A T A A N D A N A L Y S E S
